RxSight, Inc. (NASDAQ:RXST) Shares Bought by Barclays PLC

Barclays PLC boosted its holdings in shares of RxSight, Inc. (NASDAQ:RXST) by 389.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 58,786 shares of the company’s stock after purchasing an additional 46,783 shares during the period. Barclays PLC owned approximately 0.15% of RxSight worth $2,906,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in RXST. Victory Capital Management Inc. lifted its position in shares of RxSight by 21.0% during the 3rd quarter. Victory Capital Management Inc. now owns 259,864 shares of the company’s stock valued at $12,845,000 after acquiring an additional 45,161 shares during the last quarter. Algert Global LLC acquired a new stake in shares of RxSight during the second quarter worth $2,488,000. Bank of New York Mellon Corp lifted its holdings in shares of RxSight by 17.0% during the second quarter. Bank of New York Mellon Corp now owns 119,493 shares of the company’s stock valued at $7,190,000 after purchasing an additional 17,368 shares during the last quarter. Baillie Gifford & Co. boosted its position in shares of RxSight by 17.0% in the 3rd quarter. Baillie Gifford & Co. now owns 419,004 shares of the company’s stock valued at $20,711,000 after purchasing an additional 60,789 shares during the period. Finally, Ensign Peak Advisors Inc increased its stake in RxSight by 765.6% in the 2nd quarter. Ensign Peak Advisors Inc now owns 60,568 shares of the company’s stock worth $3,644,000 after purchasing an additional 53,571 shares in the last quarter. 78.78% of the stock is currently owned by institutional investors.

Insider Transactions at RxSight

In related news, Director Jesse Anderson Corley purchased 11,111 shares of RxSight stock in a transaction on Tuesday, November 12th. The stock was bought at an average price of $45.37 per share, with a total value of $504,106.07. Following the completion of the transaction, the director now directly owns 468,571 shares of the company’s stock, valued at approximately $21,259,066.27. This represents a 2.43 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Shweta Maniar sold 3,782 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $45.88, for a total value of $173,518.16. Following the sale, the director now owns 10,902 shares of the company’s stock, valued at approximately $500,183.76. This trade represents a 25.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 59,607 shares of company stock valued at $2,874,109 in the last three months. Corporate insiders own 9.36% of the company’s stock.

RxSight Trading Down 0.3 %

Shares of NASDAQ:RXST opened at $34.47 on Wednesday. The business has a fifty day simple moving average of $45.44 and a 200 day simple moving average of $49.81. RxSight, Inc. has a 1 year low of $33.03 and a 1 year high of $66.54. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -41.53 and a beta of 1.11.

Analyst Ratings Changes

A number of analysts have commented on the stock. Stifel Nicolaus lowered shares of RxSight from a “buy” rating to a “hold” rating and reduced their price objective for the company from $65.00 to $40.00 in a research note on Friday, December 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 price objective on shares of RxSight in a research note on Friday, September 13th. Wells Fargo & Company reiterated an “equal weight” rating and set a $42.00 price objective (down from $56.00) on shares of RxSight in a research report on Wednesday, December 11th. Jefferies Financial Group began coverage on RxSight in a research report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 target price for the company. Finally, UBS Group initiated coverage on RxSight in a research report on Friday, December 6th. They set a “buy” rating and a $52.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $59.00.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.